← Back to Clinical Trials
Recruiting NCT07427108

NCT07427108 Road Mapping Guided Puncture Versus Ultrasound Guided Puncture During Retrograde Angioplasty Feasibility and Safety

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07427108
Status Recruiting
Phase
Sponsor Sohag University
Condition Peripheral Arterial Disease
Study Type INTERVENTIONAL
Enrollment 32 participants
Start Date 2026-02-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Road-map guided versus US guided retrograde access

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 32 participants in total. It began in 2026-02-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study aims to compare the technical feasibility and safety of road mapping-guided versus ultrasound-guided retrograde arterial puncture in patients with (CLTI) as measured by: * Puncture success rate * Access-related complication rate (e.g., hematoma, vessel dissection, perforation)

Eligibility Criteria

Inclusion criteria: -. 1. Adults : Both male and female participants. 2. Diagnosed with critical limp threatening ischemia (CLTI): significant occlusions in the femoropopliteal o Rutherford Class 5: Non-healing wounds or ulcers 3. Failed or unable to achieve antegrade access: Patients requiring retrograde puncture for the procedure. 4. Planned intervention with retrograde access: Candidates for endovascular interventions, including angioplasty, stent deployment Exclusion criteria: • Active infection at the puncture site: Any localized infection, particularly over the ankle region , will be an exclusion. • Severe calcification or anatomical abnormalities: Patients with excessive arterial calcification or significant anatomical distortion preventing safe retrograde puncture.

Contact & Investigator

Central Contact

Yohana F Fayez, MBBCh

✉ yohana_farouz_post@med.sohag.edu.eg

📞 +201288374728

Frequently Asked Questions

Who can join the NCT07427108 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Peripheral Arterial Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07427108 currently recruiting?

Yes, NCT07427108 is actively recruiting participants. Contact the research team at yohana_farouz_post@med.sohag.edu.eg for enrollment information.

Where is the NCT07427108 trial being conducted?

This trial is being conducted at Sohag, Egypt.

Who is sponsoring the NCT07427108 clinical trial?

NCT07427108 is sponsored by Sohag University. The trial plans to enroll 32 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology